Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yukio Kobayashi, Takahiro Yamauchi, Hitoshi Kiyoi, Toru Sakura, Tomoko Hata, Kiyoshi Ando, Aiko Watabe, Akiko Harada, Tillmann Taube, Yasushi Miyazaki, Tomoki Naoe
Aineistotyyppi: Artigo
Kieli:englanti
Julkaistu: 2015
Linkit:https://doi.org/10.1111/cas.12814
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12814
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!